arrow
A

Alejandro Falcón

hospital universitario virgen del rocio
H指数:14
被引数:1,071

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial

维米塞替尼治疗腱鞘巨细胞瘤患者的多中心、开放标签、II期临床试验

Cancer
IF5.1
2026-08-300
OAAI
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project

对接受曲妥珠单抗-德鲁替卡治疗晚期乳腺癌患者UGT1A1胚系变异的分析:PROCURE项目结果

2026-05-110
OAAI
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations
2024-04-161
OAAI
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib联合西妥昔单抗治疗KRAS G12C-positive结直肠癌: 1b期临床试验

2023-12-0531
OAAI
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

单药Divarasib (GDC-6036) 在具有KRAS G12C突变的实体瘤中

2023-08-2495
OA
Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
2023-04-147
PRE
SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
2023-03-017
OA
Neopersur: Neoadjuvant pertuzumab in a real world data population in the south of Spain
2020-02-150
PRE
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
2019-11-0511
OAAI
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
2019-01-0334
PREAI